Pancreatica.org is a Clearinghouse for Current, Credible, and Comprehensive Research and Information for Pancreatic Cancer Patients

Breakthrough Treatment for advanced Pancreatic Cancer - Approved by FDA

The U.S. Food and Drug Administration has now approved the oral tablet Rasonque (daraxonrasib), a selective RAS genetic (mutation) inhibitor (present in more than 90% of those with pancreatic cancer) from the clinical oncology Revolution Medicines company. 
 
Recent findings of a Phase III U.S. clinical trial with the orally administered FDA-designated “orphan drug” daraxonrasib, which acts as a selective RAS genetic (mutation) inhibitor, were reported out by Revolution Medicines in a press release in April 2026.
The results were highly encouraging in that those in the study (all with previously treated advanced ductal adenocarcinoma of the pancreas) who received just the oral daraxonrasib alone (daily, 300 mg) doubled their overall survival duration to 13.2 months as compared to those who otherwise received standard chemotherapy (6.7 months).

Side effects were observed to be mild to moderate consisting primarily of a rash, mouth sores, and/or GI signs & symptoms.

These findings are seen as not only a new approach to treatment, but importantly as a conceptual breakthrough utilizing known biology to fashion a more precise remedy. As such, the promise could lead to other important treatment progress.